# Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05765877/  
OnCo record `nct05765877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Pingping Song, now recruiting.

## Summary

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05765877 by Pingping Song, with 26 participants planned, started 2023-03-01 and due to reach its primary completion in 2027-03. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-Small Cell Lung Cancer(NSCLC).

Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05765877
- Phase: 2
- Setting: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer: a Single-arm, Exploratory Trial
- Sponsor: Pingping Song
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT05765877: https://clinicaltrials.gov/study/NCT05765877

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Iruplinalkib](https://onco.cc/drugs/iruplinalkib/)

---
JSON: https://onco.cc/api/v1/entities/nct05765877.json